{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:50:29Z","timestamp":1792083029516,"version":"4.4.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.tjpad.2026.100653","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:20:49Z","timestamp":1786580449000},"page":"100653","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The missing improvers: Tau pathology, neuroplasticity, and the case for tau-informed patient selection before amyloid immunotherapy"],"prefix":"10.1016","volume":"13","author":[{"given":"Eric","family":"Dinnerstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.tjpad.2026.100653_bib0001","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer's disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.tjpad.2026.100653_bib0002","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer's disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100653_bib0003","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13195-025-01763-1","article-title":"Lecanemab in clinical practice: real-world outcomes in early Alzheimer's disease","volume":"17","author":"Bregman","year":"2025","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100653_bib0004","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1186\/s13195-025-01886-5","article-title":"Real-world application of lecanemab in early-stage Alzheimer\u2019s disease: a single-centre prospective cohort analysis","volume":"17","author":"Shang","year":"2025","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100653_bib0005","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13195-026-02015-6","article-title":"Real-world implementation of lecanemab and donanemab in an Italian memory centre: a 1-year experience","volume":"18","author":"Agosta","year":"2026","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.tjpad.2026.100653_bib0006","series-title":"Presented at the Alzheimer\u2019s association international conference","article-title":"Real-world use of lecanemab in patients with early Alzheimer\u2019s disease in the United States: a case series review","author":"Weisman","year":"2025"},{"key":"10.1016\/j.tjpad.2026.100653_bib0007","series-title":"Presented at the 18th clinical trials on Alzheimer's disease (CTAD)","article-title":"Real-world outcomes from the ALZ-NET national registry: first data readout","author":"Rabinovici","year":"2025"},{"issue":"4","key":"10.1016\/j.tjpad.2026.100653_bib0008","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA research framework: toward a biological definition of Alzheimer's disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement"},{"issue":"6","key":"10.1016\/j.tjpad.2026.100653_bib0009","doi-asserted-by":"crossref","first-page":"595","DOI":"10.15252\/emmm.201606210","article-title":"The amyloid hypothesis of Alzheimer's disease at 25 years","volume":"8","author":"Selkoe","year":"2016","journal-title":"EMBO Mol Med"},{"issue":"8","key":"10.1016\/j.tjpad.2026.100653_bib0010","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/nm1782","article-title":"Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory","volume":"14","author":"Shankar","year":"2008","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.tjpad.2026.100653_bib0011","doi-asserted-by":"crossref","DOI":"10.1002\/alz.70905","article-title":"Long-term safety and efficacy of lecanemab in early Alzheimer's disease: results from the clarity AD open-label extension study","volume":"21","author":"van Dyck","year":"2025","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2026.100653_bib0012","article-title":"The lecanemab clarity AD open-label extension in early Alzheimer's disease: initial findings from the 48-month analysis","author":"van Dyck","year":"2025","journal-title":"Alzheimers Dement"},{"issue":"3","key":"10.1016\/j.tjpad.2026.100653_bib0013","doi-asserted-by":"crossref","first-page":"362","DOI":"10.14283\/jpad.2023.30","article-title":"Lecanemab: appropriate use recommendations","volume":"10","author":"Cummings","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100653_bib0014","first-page":"118","article-title":"Donanemab appropriate use recommendations for patients with early symptomatic Alzheimer's disease","volume":"11","author":"Sabbagh","year":"2024","journal-title":"J Prev Alzheimers Dis"},{"issue":"11","key":"10.1016\/j.tjpad.2026.100653_bib0015","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1093\/brain\/awad188","article-title":"Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics","volume":"146","author":"Hampel","year":"2023","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100653_bib0016","doi-asserted-by":"crossref","DOI":"10.1002\/alz.14338","article-title":"Updated appropriate use criteria for amyloid and tau PET: a report from the Alzheimer's Association and SNMMI Workgroup","volume":"21","author":"Rabinovici","year":"2025","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2026.100653_bib0017","unstructured":"Centers for Medicare and Medicaid Services. Decision memo for beta amyloid positron emission tomography in dementia and neurodegenerative disease (CAG-00431R). Published October 13, 2023."},{"issue":"4","key":"10.1016\/j.tjpad.2026.100653_bib0018","first-page":"1651","article-title":"Long-term health outcomes of lecanemab in patients with early Alzheimer's disease using simulation modeling","volume":"11","author":"Tahami Monfared","year":"2022","journal-title":"Neurol Ther"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580726001779?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580726001779?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:01:25Z","timestamp":1792080085000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580726001779"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":18,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S2274580726001779"],"URL":"https:\/\/doi.org\/10.1016\/j.tjpad.2026.100653","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The missing improvers: Tau pathology, neuroplasticity, and the case for tau-informed patient selection before amyloid immunotherapy","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tjpad.2026.100653","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author. Published by Elsevier Masson SAS on behalf of SERDI Publisher.","name":"copyright","label":"Copyright"}],"article-number":"100653"}}